Familial Mediterranean Fever (FMF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Familial Mediterranean Fever (FMF) is an autoinflammatory genetic disorder characterized by recurring fevers and inflammation in the abdomen, lungs, and joints, causing severe pain. Symptoms may include a rash or headache. The onset of symptoms usually occurs in childhood and before the age of 20 years, with attacks manifesting within 2 to 4 hours and lasting 6 hours to 4 days. Mutations cause FMF in the MEFV gene on chromosome 16p13.3. Over 300 MEFV mutations have been identified, with 70 to 80% of cases attributed to V726A, M680I, E148Q, M694V, and M694I mutations. Pyrin plays a role in the pathophysiology of FMF, as it is found in the cytoskeleton of circulation cells, including white blood cells, which play a role in the immune response to pathogens. Mutations in the MEFV gene disrupt pyrin and its function, activating the inflammatory pathway through IL-1beta. Treatment for FMF involves using colchicine to prevent attacks, normalize inflammation, and prevent the development of amyloidosis. The prognosis of FMF depends on the frequency of attacks and the presence of complications, with improvement and decreased frequency of attacks typically seen with treatment. The presence of specific genotypes, such as M694V, increases the risk of complications such as renal amyloidosis and adverse prognosis. Secondary AA amyloidosis is a severe complication of FMF, with renal amyloidosis being the most common manifestation.
·
In Spain, the prevalence of familial
Mediterranean Fever is estimated to be less than 5 cases per 10,000 inhabitants.
Thelansis’s “Familial Mediterranean
Fever (FMF) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2022 To 2032" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Familial Mediterranean Fever (FMF)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Familial Mediterranean Fever (FMF) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Familial Mediterranean Fever (FMF) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven platform
that manages the data flow from primary and secondary sources.
Comments
Post a Comment